The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance

Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal. Our ambition: to become the reference player in the field of pain medication by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of first-in-class polypeptides derived from TAFA4 and its peptide derivatives. We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate, and severe -, as well as for the prevention of chronic pain.